P01: Automated Analysis of Biphasic PROTAC Dose Response Data at Scale in Drug Development, Presented by Ganesh K., AstraZeneca

P02: Design and Synthesis of A Novel Sequence Selective DNA Alkylator Against Cancer Disease, Presented by Mansour A., Auburn University

P03: 3 Steps to Maximizing Flash Purification Loading Capacity, Presented by Bob B., Biotage LLC

P04: Chemistry-Driven Hit-to-Lead Optimization Guided by Structure-Based Approaches, Presented by Philippe R., Centre National de la Recherche Scientifique (CNRS)

P05: Simulated RNA Secondary and Tertiary Structure Differences Between SARS-CoV and SARS-CoV-2 s2m Conserved Elements Consistent with NMR, Presented by Adam K., Duquesne University

P06: Modeling the SARS-CoV-2 s2m Region, Presented by Kendy P., Duquesne University

P07: SPRINTer Platform: Detection of Endogenous Protein Turnover Induced by Targeted Degraders, Presented by Chao-Tsung Y., Eurofins DiscoverX

P08: Expanding the Toolbox of E3scan Ligand Binding Assay Platform for Targeted Protein Degradation, Presented by Ksenya C., Eurofins Discovery

P09: Early Insights for Optimal Chemistry Design of Targeted Protein Degraders Using the BioMAP Human Phenotypic Platform, Presented by Alison O., Eurofins Discovery

P10: AdapTive Immune Response Models for Discovery and Repurposing in the COVID-19 Era, Presented by Alison O., Eurofins Discovery

P11: Fast and Comfortable Crystallographic Fragment Screening with the EasyAccess Frame, Presented by Tatjana B., Helmholtz-Zentrum Berlin

P12: FBDD Starting Points by Crystallography - Efficient Fragment Screening Workflow at BESSY II in Berlin, Presented by Jan W., Helmholtz-Zentrum Berlin

P13: Biocatalytic Late-Stage Oxidation for Lead Optimization, Presented by Liam E., Hypha Discovery Ltd.

P14: Discovery Process and Anti-HBV Profile of Novel Sulfamoyl Benzamide Derivatives as In Vitro and In Vivo Potent CpAM, Presented by Romano D., IRBM S.p.A.

P15: Identification of C-Terminal Derivatives of Peptide and Peptidomimetics Zika Virus NS2B-NS3 Protease Inhibitors, Presented by Jesus O., IRBM S.p.A.

P16: New Brain Penetrant Compounds in Advanced Studies: Multipotency Screening and Evaluation Against Parkinson´s Disease, Presented by Steve B., Key Organics Ltd.

P17: BIONET 2nd Generation Premium Fragment Library: Building a Diverse and Experimentally-Curated Fragment Library, Presented by Steve B., Key Organics Ltd.

P18: Improving In Silico Secondary Pharmacology Profiling Using Federated QSAR Models, Presented by Adrian F., Lhasa Ltd.

P19: DNA-Encoded Library Screening: Moving Beyond Purified Protein to Cell-Based Systems, Presented by Menglin C., Merck & Co., Inc.

P20: A Chemical Probe Based on the PreQ1 Metabolite Enables Transcriptome-Wide Mapping of Binding Sites, Presented by Sumirtha B., National Institutes of Health, National Cancer Institute

P21: Tools to Accelerate RAS-Targeted Drug Discovery and Development, Presented by Sarah D., Promega Corporation

P22: Targeted Degradation of Endogenously Tagged Proteins for Phenotypic Studies Using HaloPROTAC3 and HaloTag Technologies, Presented by Steven E., Promega Corporation

P23: NanoBRET as a Live Cell Method to Assess PROTAC Affinity, Occupancy, and Intracellular Availability for E3 Ligases, Presented by Kristin H., Promega Corporation

P24: Cell-Based Methods to Quantify Inflammasome Function and Target Engagement, Presented by Kara M., Promega Corporation

P25: Identification, Design, Synthesis, and Evaluation of Small Molecule Inhibitors of Translesion Synthesis, Presented by Angela Z., University of Connecticut, Storrs

P26: CL-FEP: A FEP-Related Estimator with Improved Convergence Properties in Explicit Solvent Calculations, Presented by Yasser RB., University of Duisburg-Essen

P27: Identification of Lead Molecule as MAS Related G Protein-Coupled Receptor X2 (MRGPRX2) Antagonist for the Treatment of Pseudo-Allergic Reactions, Presented by Mukesh K., University of Hong Kong

P28: Machine Learning for Aptamer Identification, Presented by Frances H., University of Puerto Rico

P29: Dynamic Conformational Tethering to Provide Pharmacokinetic Stability to an Electrophilic Warhead Group, Presented by Erica Q., University of Toronto at Mississauga

P30: PhosAm Linker: A Versatile Platform for Cargo Release in the Development of Targeted Cancer Therapeutics, Presented by Feyisola O., Washington State University

P31: DNA-Encoded Chemical Library (DEX) Technology and Its Application Towards TAM Kinases, Presented by Paige D., X-Chem Pharmceuticals

P32: Peptiligase Technology Platform: Traceless Native Ligation in Medicinal Chemistry and Chemical Biology, Presented by Roy B., Zuyd University of Applied Sciences